FLORIS, ALBERTO
 Distribuzione geografica
Continente #
EU - Europa 92.132
NA - Nord America 4.349
AS - Asia 2.330
SA - Sud America 330
AF - Africa 60
OC - Oceania 5
Totale 99.206
Nazione #
IT - Italia 91.170
US - Stati Uniti d'America 4.246
SG - Singapore 953
CN - Cina 662
VN - Vietnam 249
BR - Brasile 246
SE - Svezia 216
DE - Germania 171
FI - Finlandia 124
FR - Francia 104
UA - Ucraina 95
HK - Hong Kong 85
GB - Regno Unito 84
IN - India 70
CA - Canada 60
BD - Bangladesh 47
JP - Giappone 41
NL - Olanda 40
IQ - Iraq 37
AR - Argentina 30
KR - Corea 30
ES - Italia 29
ZA - Sudafrica 21
MX - Messico 19
PL - Polonia 17
PK - Pakistan 16
ID - Indonesia 15
CO - Colombia 14
IR - Iran 14
RU - Federazione Russa 12
AT - Austria 11
CL - Cile 11
UZ - Uzbekistan 11
EC - Ecuador 10
EG - Egitto 10
IE - Irlanda 10
MA - Marocco 10
CZ - Repubblica Ceca 9
IL - Israele 9
SA - Arabia Saudita 9
TR - Turchia 9
GR - Grecia 8
MY - Malesia 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
JO - Giordania 7
PH - Filippine 7
BE - Belgio 6
JM - Giamaica 6
PS - Palestinian Territory 6
AU - Australia 5
KE - Kenya 5
LT - Lituania 5
TW - Taiwan 5
UY - Uruguay 5
VE - Venezuela 5
AL - Albania 4
PY - Paraguay 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
DK - Danimarca 3
DZ - Algeria 3
ET - Etiopia 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
PA - Panama 3
TH - Thailandia 3
BG - Bulgaria 2
BY - Bielorussia 2
CR - Costa Rica 2
LV - Lettonia 2
MM - Myanmar 2
OM - Oman 2
PT - Portogallo 2
SR - Suriname 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AO - Angola 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BZ - Belize 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
PE - Perù 1
PR - Porto Rico 1
Totale 99.202
Città #
Cagliari 88.399
Uta 2.433
Singapore 548
Dallas 543
Ashburn 447
Fairfield 286
San Jose 248
Boardman 206
Woodbridge 177
Houston 172
Chandler 154
Beijing 134
Wilmington 121
Nyköping 116
Council Bluffs 113
Ann Arbor 112
Los Angeles 108
Cambridge 107
Seattle 98
Helsinki 93
Shanghai 88
Hong Kong 75
New York 75
Santa Clara 75
The Dalles 70
Ho Chi Minh City 65
Lauterbourg 61
Dong Ket 58
Dearborn 52
Munich 51
Hefei 50
Boston 45
Buffalo 43
Jacksonville 43
Rome 41
Milan 35
Hanoi 34
Chicago 32
Seoul 29
Tokyo 25
Redwood City 24
São Paulo 23
Nanjing 22
Orem 22
Amsterdam 21
Toronto 21
Frankfurt am Main 20
San Diego 20
Baghdad 19
Guangzhou 19
London 19
Montreal 19
Phoenix 18
Nuremberg 16
Warsaw 15
Brooklyn 14
Da Nang 12
Denver 12
Lappeenranta 12
Redondo Beach 12
Madrid 11
Mumbai 11
Nanchang 11
Salt Lake City 11
Tashkent 11
Chennai 10
Haiphong 10
Johannesburg 10
Turku 10
Dhaka 9
Elk Grove Village 9
Hebei 9
Shenzhen 9
Atlanta 8
Belo Horizonte 8
Changsha 8
Mountain View 8
Paris 8
Stockholm 8
Buenos Aires 7
Dublin 7
Düsseldorf 7
Guayaquil 7
Hyderabad 7
Rio de Janeiro 7
Santiago 7
Tampa 7
Tianjin 7
Washington 7
Xi'an 7
Baku 6
Brussels 6
Erbil 6
Falls Church 6
Florence 6
Manchester 6
Mexico City 6
Poplar 6
Portsmouth 6
San Francisco 6
Totale 96.338
Nome #
FRI0357 DRUG-INDUCED REMISSION AND SUBCLINICAL ACTIVITY IN PSORIATIC ARTHRITIS: TRANSCRIPTIONAL PROFILING TO CHARACTERIZE THE DISEASE STATE 10.751
Assessment Of Circulating Endothelial Cells And Their Progenitors As Potential Biomarkers Of Disease Activity And Damage Accrual In Behçet's Syndrome 3.182
Gene expression profiling of monozygotic twins affected by psoriatic arthritis 3.069
Expression analysis of HLA-E and NKG2A and NKG2C receptors points at a role for natural killer function in ankylosing spondylitis 3.066
Physician's global assessment in psoriatic arthritis: A multicenter GRAPPA study 3.028
Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus 2.904
AIF-1 gene does not confer susceptibility to Behçet's disease: Analysis of extended haplotypes in Sardinian population 2.828
Population-based analysis of hospitalizations for patients with systemic sclerosis in a West-European region over the period 2001–2012 2.824
Population-based analysis of hospitalizations in a West-European region revealed major changes in hospital utilization for patients with systemic lupus erythematosus over the period 2001-2012 2.795
Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus 2.627
Demyelinating syndrome in SLE: review of different disease subtypes and report of a case series 2.615
Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus 2.340
Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: An alternative to standard of care 2.288
Molecular modifications induced by mud-bath therapy in patients with osteoarthritis 2.262
Polymyalgia rheumatica: an autoinflammatory disorder? 2.243
Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis 2.181
PET/CT scan revealing active idiopathic inflammatory myopathy with normal serum sarcoplasmic enzymes levels 2.180
Killer-cell immunoglobulin-like receptors (KIR) and HLA-class I heavy chains in ankylosing spondylitis 2.167
Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis) 2.093
Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review 2.074
Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: Systematic literature review and analysis of a monocentric cohort 2.030
Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease 1.942
The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice 1.800
New approaches in tumor necrosis factor antagonism for the treatment of psoriatic arthritis: certolizumab pegol 1.700
Current smoking predicts inadequate response to methotrexate monotherapy in rheumatoid arthritis patients naïve to DMARDs: Results from a retrospective cohort study 1.655
Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI) 1.636
Treatment target in newly diagnosed systemic lupus erythematosus: The association of lupus low disease activity state and remission with lower accrual of early damage 1.581
Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study 1.490
Use of Physician Global Assessment in systemic lupus erythematosus: a systematic review of its psychometric properties 1.365
The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist 1.274
Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort 1.180
Targeted Therapies in Axial Psoriatic Arthritis 1.177
Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis 1.157
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study 1.086
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network 1.074
Molecular profiling of clinical remission in psoriatic arthritis reveals dysregulation of FOS and CCDC50 genes: a gene expression study 1.071
Brain-reactive autoantibodies in neuropsychiatric systemic lupus erythematosus 1.055
Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study 1.052
Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud's arthropathy and a distinctive MRI pattern 1.001
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review 930
Telemedicine in rheumatology: high specificity and sensitivity of follow-up virtual video consultations during COVID-19 pandemic 915
Patterns of Anti-Inflammatory and Immunomodulating Drug Usage and Microvascular Endothelial Function in Rheumatoid Arthritis 895
Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis 880
Organ damage is a major determinant of work productivity impairment in Behçet's Syndrome: a post-hoc analysis of the BODI validation study 877
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 864
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 852
Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study 847
Discordance between patient and physician global assessment of disease activity in Behçet’s syndrome: a multicenter study cohort 818
Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity 805
The Challenging Differentiation of Psoriatic Arthritis from Other Arthropathies and Nonspecific Arthralgias in Patients with Psoriasis: Results of a Cross-Sectional Rheumatologic Assessment of a Large Dermatologic Cohort 779
Oxidative Stress Biomarkers and Peripheral Endothelial Dysfunction in Rheumatoid Arthritis: A Monocentric Cross-Sectional Case-Control Study 767
SAT0035 IS PHARMACOLOGICAL CLINICAL REMISSION SYNONYMOUS WITH BIOLOGICAL INACTIVE DISEASE? DIFFERENTIAL GENE EXPRESSION ANALYSIS IN RHEUMATOID ARTHRITISAND HEALTY CONTROLS 722
Prevalence and clinical significance of electrocardiographic signs of atrial myopathy in rheumatoid arthritis: results from the EDRA study 568
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development 545
Quality of Life in Systemic Lupus Erythematosus and Other Chronic Diseases: Highlighting the Amplified Impact of Depressive Episodes 349
Psychometric Properties of Patient Global Assessment in Psoriatic Arthritis: A Systematic Literature Review 246
Mood Disorder Questionnaire Positivity in Systemic Lupus Erythematosus and Other Chronic Diseases including Screen Bipolar Disorders or Rhythm and Energy Dysregulation Syndromes (DYMERS) 240
Stratifying patients by TNFSF13B genotype revealed increased flare and renal flare risk, but a greater benefit from belimumab: a potential biomarker for personalized treatment in systemic lupus erythematosus 177
The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis 91
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort 88
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry 87
Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry 79
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial 66
The metabolomic profile of psoriatic arthritis patients unveils the unbalance of disease-related molecules and pathways 64
Ultrasound-Guided Synovial Biopsy Can Be Effectively and Safely Performed in Different Clinical Settings Favouring a Widespread Application of Precision Medicine in Rheumatoid Arthritis: A Post-hoc Analysis of Three Clinical Trials 52
The Risk of Developing Ocular Involvement Among Behçet’s Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet’s Disease Registry 26
The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease–related spondyloarthritis: insights from a cross-sectional study 19
The impact of demographics on organ damage in Behçet’s syndrome: a cross-sectional analysis of the international PROBE cohort 17
Rationale for investigating the use of anifrolumab in neuropsychiatric systemic lupus erythematosus: a combined narrative and case-based systematic literature review 17
Risk of major organ involvement in Behçet's patients with mucocutaneous onset: Data from the AIDA Network Registry 17
VEXAS syndrome and cancer: Insights about a possible “Tip of the Iceberg”. Ambidirectional data from the international AIDA network registries 16
Ultrasound for assessing disease activity and structural damage in psoriatic arthritis: the UPsA scores from a multicentre study by the Italian Society of Rheumatology 12
Frequency and characteristics of axial involvement in psoriatic arthritis: results from the International Multicentre AXIS Study 8
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registry 8
Phenotypic differences and treatment persistence in a large multicentre cohort of axial psoriatic arthritis 6
Totale 99.592
Categoria #
all - tutte 126.442
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.442


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021509 0 0 0 0 0 0 0 0 0 0 0 509
2021/20225.007 425 243 264 187 355 302 254 297 520 600 908 652
2022/20236.923 568 895 696 503 508 763 403 565 515 548 621 338
2023/202413.146 362 372 389 777 1.052 1.409 1.457 4.113 495 567 1.210 943
2024/202531.521 11.169 8.598 5.106 2.186 1.164 1.147 1.259 86 199 163 221 223
2025/20265.536 335 403 623 347 477 355 1.000 508 414 485 506 83
Totale 99.592